@GuiperiniMD
Pinned post
Chemo-free 1L MCL at #ASH26 (investigational):View quoted post on X
GATE1 pirto-ven-R, n=50, 34% TP53-altered: CR 96%, 12-mo PFS 96% (mFU 8 mo)
TrAVeRse acala-ven-R, n=108: 22-mo PFS 89%, TP53m 82%
TP53m pts doing well early. Next question: is MRD-neg stop safe? @YucaiWangMD #lymsm #MCL
🧬 Linfomondays | LOTIS-9
O estudo LOTIS-9 avaliou loncastuximabe tesirina associado a rituximabe em pacientes idosos, frágeis ou com contraindicação a antraciclinas com LDGCB não tratado.
📚 Confira os principais achados na Hematolog.View quoted post on X
PD(L)1-VEGF bispecifics are already beating PD1 inhibition alone in trials, so what's next?
This trial (BioNTech, DualityBio, BMS) adds a new B7-H3 ADC to a PDL1-VEGF bispecific, with potential synergy:
1) VEGF blockade: normalizes tumor vasculature, improves ADC delivery and T cell infiltration.
2) B7-H3 ADC: kills cancer cells, triggers immunogenic inflammation.
3) PDL1 blockade: releases immune suppression, allows T cells to exploit immune response induced by ADC.
Confirmed ORR up to 71% -- in immune-cold platinum-resistant ovarian cancer.
The broader, ongoing phase 2 includes colorectal cancer, pancreatic cancer and other tumor types.View quoted post on X
